Drug-eluting stent carrying short-chain ceramide

Abstract

The invention relates to a drug-eluting stent carrying therapeutically effective dose of short-chain ceramide. The stent comprises a stent body. The stent is characterized in that: the stent body carries therapeutically effective dose of short-chain ceramide. The ceramide medicine carried by the stent body provided by the invention can directly contact tumor tissues. When the stent is used in combination with total body paclitaxel anti-microtubule cytotoxic drug chemotherapy, tumor growth can be substantially inhibited, tumor cell apoptosis can be promoted, and lumen restenosis rate can be reduced. The stent body is produced from a high-molecular polymer material. The stent has good histocompatibility. When mechanical supporting with a certain period of time is accomplished, the stent is automatically degraded. The degradation product brings no toxic or side-effect to tissues, and is not necessary to be taken out by a secondary operation. A degradable polymer auxiliary agent can be added into the stent body for improving the toughness, plasticity and workability of the stent body. Degradation speed and medicine releasing speed of the stent can be regulated according to clinical requirements, such that the stent can satisfy clinical requirements, and controllability of the stent can be improved.

Description

technical field [0001] The invention belongs to the technical field of medical devices, and relates to a stent used in the local treatment of lumen stenosis caused by various malignant tumors in the human body, in particular to a drug stent carrying a therapeutically effective dose of short-chain ceramide. Background technique [0002] Tumor is the main disease that threatens human health at present, and the narrowing of human cavity caused by malignant tumor is a high incidence disease. In addition to surgical resection, radiotherapy and chemotherapy, commonly used interventional methods mainly include stent placement. For patients with advanced tumors, stent placement is a very important palliative treatment method, which can effectively improve the quality of life and prolong the survival time of patients with advanced tumors. [0003] However, traditional metal stents and covered stents have at least two disadvantages: (1) Metal stents do not have a real local therapeut...

AI Technical Summary

Problems solved by technology

[0003] However, traditional metal stents and covered stents have at least two disadvantages: (1) Metal stents do not have a real local therapeutic effect, but only provide mechanical support and short-term palliative effects, and are powerless to prevent restenosis caused by tumor growth ; Although covered stents can prevent tumor in-growth to a certain extent, they still cannot prevent tumor longitudinal overgrowth and compressive restenosis

(2) After metal stent implantation, systemic administration is still required. However, after systemic administration, the blood drug concentration in cancer tissue is low, and it is difficult to achieve an effective therapeutic concentration. If a certain tumor suppression effect is to be achieved, large-scale Long-term chemotherapy, but most anticancer drugs have severe side effects

"However, the disadvantages of this stent are: first, the patent is only limited to the digestive tract, and is not applicable to other natural lumens such as the urethra, prostatic tract, and airway; second, the anticancer drugs of the stent are limited to the above-mentioned Several categories

However, exogenous short-chain ceramide alone cannot effectively induce apoptosis in most tumor cells

Images